CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF557 (ImmuneEditome ID:79230)

1. Gene summary of enriched editing regions for ZNF557

check button Gene summary
Gene informationGene symbol

ZNF557

Gene ID

79230

GeneSynonyms-
GeneCytomap

19p13.2

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 557|CTB-25J19.9
GeneModificationdate20230518
UniprotIDQ8N988
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:7084333-7087595:+ENST00000414706.2ENSG00000130544.10ZNF557UTR3AluY,AluSp,AluSq,AluSx1,(T)n,AluJbchr19:7084333-7087595:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF557


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:7084333-7087595:+BLCAPathEER2.1699e-025.6897e-030.2125image
ENSG00000130544.10,ZNF557BLCAPathEAG2.1699e-025.6897e-030.2125image
chr19:7084333-7087595:+ESCACliEER1.7131e-023.0620e-02-0.3192image
ENSG00000130544.10,ZNF557ESCACliEAG9.8100e-031.3742e-02-0.3609image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF557


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:7084333-7087595:+ESCAEERENSG00000130544,ZNF557-0.40591.3704e-031.6464e-07-0.4308imageNADAR;AIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZC3H7B;ZFP36;ZNF184NAMonocytesGSVA_HALLMARK_HYPOXIA
chr19:7084333-7087595:+TGCTEERENSG00000165724,ZMYND19-0.44947.8860e-059.4536e-07-0.4368imageNAIFM1;CNBP;CSTF2T;DHX9;EIF4A3;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
chr19:7084333-7087595:+TGCTEERENSG00000126249,PDCD2L-0.41122.2848e-046.7218e-08-0.4758imageNCNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;ZC3H7B;ZFP36;ZNF184PDCD2LMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
chr19:7084333-7087595:+TGCTEERENSG00000185163,DDX51-0.42662.4224e-042.7137e-06-0.4198imageNADAR;AIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr19:7084333-7087595:+TGCTEERENSG00000132128,LRRC410.40462.7443e-042.9111e-080.4872imageNADAR;AIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr19:7084333-7087595:+TGCTEERENSG00000176101,SSNA1-0.40673.6586e-046.7491e-06-0.4043imageNAIFM1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
chr19:7084333-7087595:+TGCTEERENSG00000160214,RRP1-0.41354.0405e-042.6114e-06-0.4205imageNAIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr19:7084333-7087595:+TGCTEERENSG00000160908,ZNF394-0.40654.1052e-043.4143e-06-0.4160imageNADAR;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
chr19:7084333-7087595:+TGCTEERENSG00000170468,C14orf169-0.37544.8750e-044.5037e-06-0.4113imageNCNBP;DICER1;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28B;MOV10;MSI2;NOP58;PTBP1;SLTM;SND1;SRSF1;SRSF9;TAF15;U2AF2;UPF1;YTHDF1NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
chr19:7084333-7087595:+TGCTEERENSG00000099821,POLRMT-0.39555.2559e-048.3710e-07-0.4388imageNADAR;AIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for ZNF557


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:7084333-7087595:+
ESCAEERIRENSG00000162066.10chr162528351:2528718:2529474:2529517-0.33823.5251e-034.3141e-06-0.4088imageNAIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZNF184NAGSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000130544.10,ZNF557
ESCAEAGIRENSG00000162066.10chr162528351:2528718:2529474:2529517-0.35571.5080e-032.1501e-06-0.4203imageNAIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAGSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000130544.10,ZNF557
OVEAGESENSG00000112200.12chr657147089:57148693:57150718:57150862:57152220:57152351-0.16512.1298e-021.8225e-10-0.4479imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZFP36;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:7084333-7087595:+
OVEERESENSG00000112200.12chr657147089:57148693:57150718:57150862:57152220:57152351-0.16342.0149e-022.1447e-10-0.4464imageNADAR;AIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZC3H7B;ZFP36;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
ENSG00000130544.10,ZNF557
TGCTEAGA5ENSG00000100711.9chr14103732619:103732762:103729090:103729182:103729090:1037298460.33243.1617e-022.2419e-070.4587imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:7084333-7087595:+
TGCTEERA5ENSG00000196547.10chr1590918193:90918388:90916122:90916256:90916122:909166600.35627.9679e-031.1765e-050.4062imageNADAR;AIFM1;CNBP;CSTF2T;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZFP36;ZNF184NAB_cells_naiveGSVA_HALLMARK_MYOGENESIS
ENSG00000130544.10,ZNF557
TGCTEAGIRENSG00000111664.6chr126843631:6845802:6846791:6846898-0.33932.0096e-029.8171e-06-0.4095imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CSTF2T;DGCR8;DHX9;DICER1;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SF3A3;SF3B4;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAMacrophages_M2GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:7084333-7087595:+
TGCTEERA3ENSG00000122678.10chr744078739:44078811:44073782:44074530:44073782:440766290.36423.3330e-037.1672e-060.4281imageNADAR;AIFM1;CNBP;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:7084333-7087595:+
TGCTEERIRENSG00000111664.6chr126843631:6845802:6846791:6846898-0.33932.1553e-029.8171e-06-0.4095imageNAIFM1;CSTF2T;DHX9;DICER1;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;SND1;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000130544.10,ZNF557
TGCTEAGIRENSG00000250571.2chr8143267432:143267484:143269359:1432695200.33531.6845e-021.4592e-050.4022imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28B;LSM11;MBNL1;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

5. Enriched editing regions and immune infiltration for ZNF557


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:7084333-7087595:+BLCAEERB_cells_naive3.1960e-040.2752image
ENSG00000130544.10,ZNF557BLCAEAGB_cells_naive3.1960e-040.2752image
chr19:7084333-7087595:+BRCAEERMast_cells_activated1.7262e-020.0827image
ENSG00000130544.10,ZNF557BRCAEAGMast_cells_activated1.7262e-020.0827image
chr19:7084333-7087595:+CESCEERT_cells_CD84.7079e-02-0.1706image
ENSG00000130544.10,ZNF557CESCEAGT_cells_CD84.7079e-02-0.1706image
chr19:7084333-7087595:+COADEERDendritic_cells_activated2.0807e-030.3867image
ENSG00000130544.10,ZNF557COADEAGDendritic_cells_activated2.0807e-030.3867image
chr19:7084333-7087595:+ESCAEERMast_cells_resting1.4844e-02-0.2085image
ENSG00000130544.10,ZNF557ESCAEAGMast_cells_resting1.5690e-02-0.2068image
chr19:7084333-7087595:+GBMEERMast_cells_resting6.6137e-050.3295image
ENSG00000130544.10,ZNF557GBMEAGMast_cells_resting6.6137e-050.3295image
chr19:7084333-7087595:+HNSCEERMast_cells_activated5.5538e-030.2538image
ENSG00000130544.10,ZNF557HNSCEAGMast_cells_activated5.5538e-030.2538image
chr19:7084333-7087595:+KIRCEERDendritic_cells_resting2.8977e-030.2036image
ENSG00000130544.10,ZNF557KIRCEAGDendritic_cells_resting2.8977e-030.2036image
ENSG00000130544.10,ZNF557LAMLEAGT_cells_CD4_memory_activated3.1801e-020.2569image
chr19:7084333-7087595:+LGGEERMast_cells_activated1.1654e-020.1482image
ENSG00000130544.10,ZNF557LGGEAGMast_cells_activated1.1654e-020.1482image
ENSG00000130544.10,ZNF557LIHCEAGEosinophils5.9999e-040.4869image
chr19:7084333-7087595:+LUSCEERT_cells_CD4_memory_activated1.3673e-020.1649image
ENSG00000130544.10,ZNF557LUSCEAGT_cells_CD4_memory_activated1.3673e-020.1649image
chr19:7084333-7087595:+OVEERT_cells_gamma_delta3.1942e-02-0.1354image
ENSG00000130544.10,ZNF557OVEAGT_cells_gamma_delta3.4978e-02-0.1332image
ENSG00000130544.10,ZNF557PAADEAGMast_cells_activated4.7973e-02-0.2756image
chr19:7084333-7087595:+PCPGEERDendritic_cells_activated1.2053e-020.2386image
ENSG00000130544.10,ZNF557PCPGEAGDendritic_cells_activated1.2053e-020.2386image
chr19:7084333-7087595:+PRADEERT_cells_CD4_memory_resting7.8916e-030.1557image
ENSG00000130544.10,ZNF557PRADEAGT_cells_CD4_memory_resting8.0185e-030.1554image
chr19:7084333-7087595:+SARCEERT_cells_regulatory_(Tregs)3.9433e-020.1596image
ENSG00000130544.10,ZNF557SARCEAGT_cells_regulatory_(Tregs)3.9444e-020.1596image
chr19:7084333-7087595:+SKCMEERMacrophages_M01.5480e-020.1727image
ENSG00000130544.10,ZNF557SKCMEAGMacrophages_M01.5480e-020.1727image
ENSG00000130544.10,ZNF557STADEAGT_cells_follicular_helper4.5468e-020.1176image
chr19:7084333-7087595:+TGCTEERMacrophages_M22.2911e-060.4226image
ENSG00000130544.10,ZNF557TGCTEAGMacrophages_M22.2911e-060.4226image
chr19:7084333-7087595:+THCAEERDendritic_cells_activated3.3306e-020.1190image
ENSG00000130544.10,ZNF557THCAEAGDendritic_cells_activated3.3306e-020.1190image
chr19:7084333-7087595:+UCECEERT_cells_CD4_naive8.4415e-040.3270image
ENSG00000130544.10,ZNF557UCECEAGT_cells_CD4_naive8.2997e-040.3275image
chr19:7084333-7087595:+UCSEERMacrophages_M02.9042e-020.3988image
ENSG00000130544.10,ZNF557UCSEAGMacrophages_M02.9042e-020.3988image


Top

6. Enriched editing regions and immune gene sets for ZNF557


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000130544.10,ZNF557ACCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG9.6875e-03-0.4313image
chr19:7084333-7087595:+BLCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER8.9273e-030.2018image
ENSG00000130544.10,ZNF557BLCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.9273e-030.2018image
chr19:7084333-7087595:+BRCAGSVA_HALLMARK_HYPOXIAEER1.0610e-080.1972image
ENSG00000130544.10,ZNF557BRCAGSVA_HALLMARK_HYPOXIAEAG1.0610e-080.1972image
chr19:7084333-7087595:+CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.1899e-020.2151image
ENSG00000130544.10,ZNF557CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.1899e-020.2151image
chr19:7084333-7087595:+ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER9.6406e-03-0.2212image
ENSG00000130544.10,ZNF557ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG8.0226e-03-0.2265image
chr19:7084333-7087595:+GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.6404e-040.2833image
ENSG00000130544.10,ZNF557GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG6.6404e-040.2833image
chr19:7084333-7087595:+KIRPGSVA_HALLMARK_HYPOXIAEER1.2874e-030.2917image
ENSG00000130544.10,ZNF557KIRPGSVA_HALLMARK_HYPOXIAEAG1.1634e-030.2930image
ENSG00000130544.10,ZNF557LGGGSVA_HALLMARK_G2M_CHECKPOINTEAG1.9885e-04-0.2172image
chr19:7084333-7087595:+LGGGSVA_HALLMARK_G2M_CHECKPOINTEER1.9885e-04-0.2172image
ENSG00000130544.10,ZNF557LIHCGSVA_HALLMARK_SPERMATOGENESISEAG3.5458e-02-0.3109image
ENSG00000130544.10,ZNF557LUSCGSVA_HALLMARK_UV_RESPONSE_UPEAG4.2902e-030.1906image
chr19:7084333-7087595:+LUSCGSVA_HALLMARK_UV_RESPONSE_UPEER4.2902e-030.1906image
chr19:7084333-7087595:+OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.7624e-030.1706image
ENSG00000130544.10,ZNF557OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.6908e-030.1708image
ENSG00000130544.10,ZNF557PAADGSVA_HALLMARK_APICAL_SURFACEEAG6.5287e-030.3726image
ENSG00000130544.10,ZNF557SARCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.2782e-040.2654image
chr19:7084333-7087595:+SARCGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.2711e-040.2654image
ENSG00000130544.10,ZNF557SKCMGSVA_HALLMARK_MYOGENESISEAG4.6141e-020.1426image
chr19:7084333-7087595:+SKCMGSVA_HALLMARK_MYOGENESISEER4.6141e-020.1426image
chr19:7084333-7087595:+STADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.4965e-020.1182image
ENSG00000130544.10,ZNF557STADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.4644e-020.1180image
chr19:7084333-7087595:+TGCTGSVA_HALLMARK_UV_RESPONSE_DNEER5.4066e-060.4082image
ENSG00000130544.10,ZNF557TGCTGSVA_HALLMARK_UV_RESPONSE_DNEAG5.4066e-060.4082image
chr19:7084333-7087595:+THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.8270e-030.1664image
ENSG00000130544.10,ZNF557THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.8270e-030.1664image
chr19:7084333-7087595:+UCECGSVA_HALLMARK_APICAL_JUNCTIONEER2.5208e-030.2974image
ENSG00000130544.10,ZNF557UCECGSVA_HALLMARK_APICAL_JUNCTIONEAG2.4124e-030.2987image
chr19:7084333-7087595:+UCSGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.4472e-03-0.5169image
ENSG00000130544.10,ZNF557UCSGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.4472e-03-0.5169image


Top

7. Enriched editing regions and drugs for ZNF557


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000130544.10,ZNF557ACCEmbelinEAG1.2834e-020.4164image
chr19:7084333-7087595:+BLCAGSK.650394EER5.2267e-030.2152image
ENSG00000130544.10,ZNF557BLCAGSK.650394EAG5.2267e-030.2152image
chr19:7084333-7087595:+BRCAAZD.0530EER2.2246e-04-0.1280image
ENSG00000130544.10,ZNF557BRCAAZD.0530EAG2.2246e-04-0.1280image
chr19:7084333-7087595:+CESCABT.263EER1.7399e-020.2037image
ENSG00000130544.10,ZNF557CESCABT.263EAG1.7399e-020.2037image
ENSG00000130544.10,ZNF557COADFTI.277EAG2.5847e-020.2853image
chr19:7084333-7087595:+COADFTI.277EER2.5847e-020.2853image
ENSG00000130544.10,ZNF557ESCAGefitinibEAG2.3684e-02-0.1946image
chr19:7084333-7087595:+ESCAGefitinibEER1.3930e-02-0.2112image
ENSG00000130544.10,ZNF557GBMLenalidomideEAG7.3526e-050.3275image
chr19:7084333-7087595:+GBMLenalidomideEER7.3526e-050.3275image
ENSG00000130544.10,ZNF557HNSCJW.7.52.1EAG1.3386e-020.2271image
chr19:7084333-7087595:+HNSCJW.7.52.1EER1.3386e-020.2271image
chr19:7084333-7087595:+KICHFH535EER3.2035e-02-0.3859image
ENSG00000130544.10,ZNF557KICHFH535EAG3.2035e-02-0.3859image
chr19:7084333-7087595:+KIRCBleomycinEER1.9438e-020.1604image
ENSG00000130544.10,ZNF557KIRCBleomycinEAG1.9438e-020.1604image
chr19:7084333-7087595:+KIRPDMOGEER3.2426e-02-0.1963image
ENSG00000130544.10,ZNF557KIRPDMOGEAG3.5315e-02-0.1924image
ENSG00000130544.10,ZNF557LAMLGSK269962AEAG2.7080e-020.2642image
chr19:7084333-7087595:+LGGIPA.3EER3.7368e-040.2079image
ENSG00000130544.10,ZNF557LGGIPA.3EAG3.7368e-040.2079image
ENSG00000130544.10,ZNF557LIHCJNK.9LEAG1.2936e-02-0.3638image
chr19:7084333-7087595:+LUADBMS.754807EER6.1555e-030.2364image
ENSG00000130544.10,ZNF557LUADBMS.754807EAG6.1555e-030.2364image
chr19:7084333-7087595:+LUSCBMS.708163EER4.3691e-03-0.1902image
ENSG00000130544.10,ZNF557LUSCBMS.708163EAG4.3691e-03-0.1902image
chr19:7084333-7087595:+MESOLenalidomideEER5.6692e-03-0.4710image
ENSG00000130544.10,ZNF557MESOLenalidomideEAG5.6692e-03-0.4710image
chr19:7084333-7087595:+OVMethotrexateEER1.8015e-020.1495image
ENSG00000130544.10,ZNF557OVMethotrexateEAG1.8433e-020.1490image
ENSG00000130544.10,ZNF557PAADErlotinibEAG2.4059e-02-0.3220image
ENSG00000130544.10,ZNF557PCPGEmbelinEAG3.9185e-040.3322image
chr19:7084333-7087595:+PCPGEmbelinEER3.9185e-040.3322image
chr19:7084333-7087595:+PRADAxitinibEER4.5927e-020.1173image
ENSG00000130544.10,ZNF557PRADAxitinibEAG4.6359e-020.1171image
chr19:7084333-7087595:+SARCJNJ.26854165EER1.5419e-03-0.2432image
ENSG00000130544.10,ZNF557SARCJNJ.26854165EAG1.5415e-03-0.2432image
chr19:7084333-7087595:+STADDoxorubicinEER4.2462e-030.1680image
ENSG00000130544.10,ZNF557STADBAY.61.3606EAG5.6675e-030.1621image
chr19:7084333-7087595:+TGCTBIRB.0796EER2.9564e-070.4546image
ENSG00000130544.10,ZNF557TGCTBIRB.0796EAG2.9564e-070.4546image
ENSG00000130544.10,ZNF557THCAAKT.inhibitor.VIIIEAG4.0527e-02-0.1146image
chr19:7084333-7087595:+THCAAKT.inhibitor.VIIIEER4.0527e-02-0.1146image
chr19:7084333-7087595:+THYMDasatinibEER2.8410e-02-0.2192image
ENSG00000130544.10,ZNF557THYMDasatinibEAG2.8410e-02-0.2192image
chr19:7084333-7087595:+UCECFTI.277EER3.9695e-03-0.2842image
ENSG00000130544.10,ZNF557UCECFTI.277EAG3.7894e-03-0.2856image
ENSG00000130544.10,ZNF557UCSFTI.277EAG9.2962e-04-0.5732image
chr19:7084333-7087595:+UCSFTI.277EER9.2962e-04-0.5732image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType